Stocktoria
Corvus Pharmaceuticals, Inc. CRVS
Corvus Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $33.7M | — | — | $19.4M | $16.5M | $24.5M | $29.1M | $31.8M | $38.0M | $38.6M |
| Operating income | -$43.0M | — | — | -$27.5M | -$23.4M | -$32.6M | -$38.6M | -$43.8M | -$48.9M | -$49.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.3M | — | — | -$62.3M | -$27.0M | -$41.3M | -$43.2M | -$6.0M | -$46.7M | -$46.9M |
| EPS (diluted) | $-0.53 | — | — | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 | $-1.59 | — |
| Operating cash flow | -$32.8M | — | — | -$25.4M | -$23.9M | -$27.0M | -$36.7M | -$34.8M | -$37.3M | -$41.0M |
| Free cash flow | -$33.0M | — | — | — | -$24.0M | -$27.3M | -$36.7M | -$34.9M | -$37.3M | -$41.3M |
| Cash & equivalents | $4.6M | $14.7M | $5.0M | $8.7M | $12.6M | $13.2M | $63.5M | $16.5M | $5.2M | $39.2M |
| Total assets | $71.1M | $89.5M | $59.4M | $68.9M | $45.6M | $68.2M | $109.5M | $85.5M | $83.6M | $118.2M |
| Total liabilities | $9.9M | $9.2M | $10.1M | $36.3M | $6.9M | $12.1M | $12.3M | $13.4M | $12.5M | $7.9M |
| Shareholders' equity | $61.2M | $80.2M | $49.3M | $32.6M | $38.7M | $56.1M | $97.2M | $72.1M | $71.1M | $110.3M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.